Publication: Management of severe atopic dermatitis with thymostimulin
Issued Date
2002-08-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0036702888
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.85, No.SUPPL. 2 (2002)
Suggested Citation
Wanee Wisuthsarewong, Suchitra Viravan Management of severe atopic dermatitis with thymostimulin. Journal of the Medical Association of Thailand. Vol.85, No.SUPPL. 2 (2002). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/20438
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Management of severe atopic dermatitis with thymostimulin
Author(s)
Other Contributor(s)
Abstract
Two patients with severe atopic dermatitis unresponsive to conventional therapy were enrolled in a clinical trial on thymostimulin (TP-1). TP-1 was administered by subcutaneous injection 1 mg/kg/day for 14 days and then 1 mg/kg/day on alternate days for 2 months. Clinical and immunological status were evaluated at baseline and at regular intervals during the treatment. Clinical severity scores included eight skin conditions (erythema, edema, vesicle, crust, excoriation, scaling, lichenification, pigmentation), two subjective components (itchiness and loss of sleep), and extent of area affected. There was a statistically significant improvement in the overall assessment of the severity scores. There were no definite changes in immunological parameters including CD4, CD8 T-cell subpopulations and serum IgE, but eosinophil count showed a mark decrease in one case. No serious side effects were observed.